Showing results (51-60 of 122) with videos related to

Sort By:
Pageof 13
British Journal of Haematology|June 29, 2006
In vivo and in vitro cytotoxicity of R-etodolac with dexamethasone in glucocorticoid-resistant multiple myeloma cellsPaola Neri, Hiroshi Yasui, Teru Hideshima, et al.
Haematologica|August 20, 2016
Synergistic DNA-damaging effect in multiple myeloma with the combination of zalypsis, bortezomib and dexamethasoneAna-Alicia López-Iglesias, Lorena González-Méndez, Laura San-Segundo, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 30, 2023
Real-World Health Care Services Utilization Associated With the Management of Patients With Relapsed and Refractory Multiple Myeloma in Spain: The CharisMMa StudyEnrique M Ocio, Carmen Montes-Gaisán, Gabriela Bustamante, et al.
Leukemia|May 16, 2020
A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myelomaJoseph Mikhael, Joshua Richter, Ravi Vij, et al.
International Journal of Molecular Sciences|May 11, 2024
Tinostamustine (EDO-S101), an Alkylating Deacetylase Inhibitor, Enhances the Efficacy of Daratumumab in Multiple Myeloma by Upregulation of CD38 and NKG2D LigandsAndrea Díaz-Tejedor, Javier Rodríguez-Ubreva, Laura Ciudad, et al.
Blood|November 21, 2008
Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaksEnrique M Ocio, Patricia Maiso, Xi Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2008
Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's MacroglobulinemiaMeletios Athanasios Dimopoulos, Morie A Gertz, Efstathios Kastritis, et al.
Plos One|April 28, 2012
Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effectsAntonio Garcia-Gomez, Enrique M Ocio, Edvan Crusoe, et al.
Blood|August 6, 2011
BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patientsGiuseppe Visani, Lara Malerba, Pietro Maria Stefani, et al.
British Journal of Haematology|April 10, 2008
p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implicationsKenji Ishitsuka, Teru Hideshima, Paola Neri, et al.
Pageof 13